Your Position: Home > Journal List > CHINA MEDICINE > Paper

The impact of aggressive statin treatment prior to percutaneous coronary intervention on patients with non-ST segment elevation acute coronary syndrome on cardiovascular events

( views:212, downloads:0 )
Author:
YANG Jie-ying(Department of Cardiology,Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
WANG Fei(Department of Cardiology,Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
YU Ying(Department of Cardiology,Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
LI Jin-xiang(Department of Cardiology,Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
CHEN Shu-yan(Department of Cardiology,Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
Journal Title:
CHINA MEDICINE
Issue:
Volume 06, Issue 07, 2011
DOI:
10.3760/cma.j.issn.1673-4777.2011.07.001
Key Word:
Non-ST segment elevation acute coronary syndrome;Angioplasty,transluminal,percutaneous coronary;Statins;Myocardial injury

Abstract: Objective To observe the impact of aggressive statin treatment prior to percutaneous coronary intervention (PCI) in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) on cardiovascular events.Methods One hundred NSTE-ACS patients were enroned and randomized into 2 groups:standard and aggressive statin treatment.The standard group received simvastatin 20 mg per day and the aggressive statin treatment group received atorvastatin 40 mg per day for 7 days prior to PCI,respectively.Both groups received other standard medical therapy.Biomarkers of cardiac injury were measured and compared before and after PCI.Major cardiovascular adverse events were evaluated during one month period of follow-up.Results Both CK-MB and TnI levels were significantly reduced after aggressive statin treatment compared to standard dose(P<0.05).After PCI,CKMB and TnI levels were significantly elevated in NSTE-ACS patients with standard dose than in patients with aggressive statin treatment(P<0.05).Major cardiovascular adverse events were reduced in aggressive statin treatment group,however,no statistical difference was observed between the two groups.Conclusion Aggressive statin treatment prior to PCI may be more effective in reducing post-PCI myocardial injury than normal dose of statin therapy in NSTE-ACS patients.

  • [1]Brener SJ,Ellis SG,Schneider J,et al.Frequency and long-term impact of myonecrosis after coronary stenting.Eur Heart J,2002,23(11):869-876.
  • [2]Wolfrum S,Dendoffer A,Schua M,et al.Simvastatin acutely reduces myocardial reperfusion injury in viva by activating the phosphatidylinositide 3-kinase/Akt pathway.J Cardiovaac Phmanacol,2004,44(3):348-355.
  • [3]Patti G,Paaceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDAACS randomized trial.J Am Coll Cardiol,2007,40(12):1272-1278.
  • [4]Kngelmass AD,Cohen DJ,Moscucci M,et al.Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting.Am J Cardiol,1994,74(8):748-754.
  • [5]Harrington RA,Lincoff AM,Califf RIM,et al.Characteristics and consequences of myocardial infarction after percutaneous coronary intervention:insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).J Am Coil Cardiol,1995,25(7):1693-1699.
  • [6]Cannon CP,Weintraub WS,Demopoulos LA,et al.Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ⅱb/Ⅲa inhibitor tirofiban.N Engl J Med,2001,344(25):1879-1887.
  • [7]Tardiff BE,Califf RM,Tcheng JE,et al.Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneons intervention.IMPACT-Ⅱ Investigators.Integrilin(eptifibatide) to Minimize Platelet Aggregation and Coronary ThrombosisⅡ.J Am Coil Cardiol,1999,33(1):88-96.
  • [8]Januzzi JL,Hahn SS,Chae CU,et al.Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.Am J Cardiol,2000,86(7):713-717.
  • [9]Briguori C,Colombo A,Airoldi F,et al.Statin administration before percutsneous coronary intervention:impact on periprocedural myocardial infarction.Eur Heart J,2004,25(20):1822-1828.
  • [10]Paseeri V,Patti G,Nuaca A,et al.Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention:results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty)study.Circulation,2004,110(6):674-648.
  • [11]Hao PP,Chen YG,Wang JL,et al.Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease.Clin Exp Pharmacol Physid,2010,37(4):496-500.
  • [12]Eto M,Rathgeb L,C06entino F,et al.Statins blunt thrombin-in-dueed down-regulation of endothelial nitric oxide synthase expression in human endothelial cells.J Cardiovaso Pharmacol,2006,47(5):663-667.
  • [13]Undas A,Bmmmel-Ziedins KE,Potaczek DP,et al.Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.J Thromb Hacmost,2006,4 (11):2397-2404.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn